Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Rarimo, a zero-knowledge (ZK) identity protocol, has announced the closing of a $2.5 million fundraising round spearheaded by ...

Next-generation sequencing refers to non-Sanger-based high-throughput DNA sequencing technologies. Millions or billions of DNA strands can be sequenced in parallel, yielding substantially more ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

Vyriad's targeted lentiviral vector platform provides T ... Inc. Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered ...

It’s an interesting place to start both because it obviously addresses the overlap of generation and politics and because it gets at a fundamental aspect of generations: They are, in fact ...

The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...

“As part of our regular portfolio assessment, we have made the strategic decision to deprioritize ex vivo lentiviral-based ... but the earlier-generation technology has its share of problems ...